Instem Reinforces Commitment to End-to-End Preclinical Solutions Amid Evolving Regulatory Landscape
In response to the FDA’s recent announcement expanding flexibility in preclinical submission evidence, Instem, a global leader in life sciences technology, is reaffirming its position as the industry’s trusted provider of an end-to-end preclinical platform. This development underscores Instem’s ongoing mission to empower life sciences organizations with the tools, insights, and scientific expertise needed to navigate an increasingly dynamic regulatory environment.
While some view the FDA’s shift as a significant change in direction, Instem sees it as a natural evolution—building on years of collaboration with clients worldwide to modernize preclinical research methodologies. The company has long championed the integration of traditional in vivo studies with innovative, data-driven approaches, ensuring that life sciences organizations can adapt without compromising scientific rigor or compliance.
A Natural Evolution in Preclinical Research
“This has long been the trajectory: traditional in vivo research studies are here to stay, but this latest development supplements these proven methods with more predictive, flexible, and data-driven approaches,” said Vik Krishnan, CEO of Instem. “We are not surprised and are very supportive of the FDA’s direction. Instem is uniquely positioned to help clients adapt—not by replacing what works, but by expanding what’s possible.”
The FDA’s expanded flexibility allows for the inclusion of New Alternative Methodologies (NAMs) alongside traditional preclinical studies, enabling researchers to incorporate advanced predictive models, in vitro experiments, and other innovative techniques. This approach reduces reliance on animal testing while enhancing the quality and relevance of preclinical data. For Instem, this regulatory evolution aligns perfectly with its comprehensive platform, which supports both conventional and emerging methodologies.
Comprehensive Solutions for a Dynamic Regulatory Environment
Instem’s platform is designed to address the multifaceted needs of modern preclinical research, ensuring that sponsors and contract research organizations (CROs) can confidently plan, execute, and submit studies. Key components of the platform include:
- Study Management
Instem’s solutions support both traditional GLP (Good Laboratory Practice) workflows and non-GLP methodologies, offering flexible modular study designs and advanced planning tools. These capabilities enable researchers to design complex preclinical programs with precision and adaptability, whether they’re working with traditional in vivo models or exploring New Alternative Methodologies. - In Silico Predictive Modeling
Instem provides cutting-edge predictive modeling and analytics tools that empower researchers to explore mechanism-based alternatives and make informed early decisions. By reducing reliance on in vivo testing, these tools not only enhance efficiency but also align with the growing emphasis on ethical and sustainable research practices. - In Vitro Data Integration
Instem’s platform seamlessly integrates laboratory data from in vitro experiments, enabling structured capture, analysis, and visualization across diverse modalities. This functionality ensures that non-traditional data sources are incorporated into the broader preclinical workflow, supporting a more holistic understanding of study outcomes. - Regulatory Submission Support
In this new era of mixed-method evidence, Instem’s Submit suite is more essential than ever. The platform offers robust, compliant pathways for structured submission and SEND (Standard for Exchange of Nonclinical Data) generation, accommodating varied evidence types and ensuring regulatory readiness at every step.
Leadership in Innovation and Collaboration
Instem’s commitment to advancing preclinical research extends beyond its platform. The company is an active member of the VICT3R consortium, a collaborative initiative driving innovation in regulatory toxicology through virtual control groups and advanced data science. By participating in such initiatives, Instem continues to shape the future of preclinical research while addressing the evolving needs of its clients.
“Our mission hasn’t changed,” added Krishnan. “Our mission is to help our customers make discoveries and accelerate their research programs. Our customers are able to make better decisions, run programs that are faster, more effective, and have less risk. As the regulatory environment evolves, that mission—and our end-to-end platform—becomes even more critical.”
Empowering Life Sciences Organizations Worldwide
As regulatory requirements become more complex and flexible, Instem’s end-to-end preclinical platform stands out as a vital resource for global sponsors and CROs. By providing tools that ensure scientific rigor, compliance, and adaptability, Instem enables organizations to thrive in an ever-changing landscape.
The company’s ability to integrate traditional in vivo studies with New Alternative Methodologies positions it as a leader in the transition toward more predictive and efficient preclinical research. Whether through advanced predictive modeling, seamless in vitro data integration, or robust regulatory submission support, Instem equips researchers with the capabilities needed to succeed.
Why This Matters for the Future of Preclinical Research
The FDA’s expanded flexibility in preclinical submission evidence reflects a broader trend toward innovation and adaptability in life sciences research. By embracing New Alternative Methodologies and advanced data-driven approaches, organizations can reduce reliance on animal testing, improve the quality of their data, and accelerate the drug development process.
For Instem, this regulatory shift reinforces the importance of its mission: to provide life sciences organizations with the tools and insights needed to make groundbreaking discoveries. As the industry continues to evolve, Instem remains committed to helping its clients navigate challenges, seize opportunities, and drive meaningful advancements in preclinical research.
About Instem
Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
